XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint. Specifically, the Company noted that "substantial irregularities that make unequivocal interpretation of the findings difficult."
Following this news, XBiotech's stock price sharply fell during intraday trading on the same day.
To receive more information, please fill out the form.
